Literature DB >> 6271838

Comparative trial of the antiemetic effects of THC and haloperidol.

J A Neidhart, M M Gagen, H E Wilson, D C Young.   

Abstract

A prospective, randomized and double-blinded trial of the comparative effects of delta-9-tetrahydrocannabinol (THC) and haloperidol (H) was begun in February 1980. Patients were randomized to initially receive either THC or haloperidol with cross-over to the other agent after two courses. All patients evaluated efficacy and toxicity of each agent and those patients completing the study expressed a preference for either THC or haloperidol. All patients are receiving chemotherapeutic agents known to induce severe vomiting (cis-platinum, nitrogen mustard, or doxorubicin) or have a history or retching with chemotherapy. Fifty-two patients are evaluable as of October, 1980. THC and haloperidol were equally effective in controlling nausea and vomiting as judged by number of vomiting episodes, patient evaluation of efficacy, and patient preference. About 10% of patients had complete control of vomiting and a third had less than five episodes. Patients failing one of the antiemetics had good control with the other about half the time. Toxicities from THC were less well tolerated than those from haloperidol, but most patients had no serious side effects. Nonoverlapping toxicities and efficacy raise the possibility that a combination of the agents might be worthwhile.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271838     DOI: 10.1002/j.1552-4604.1981.tb02571.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.

Authors:  M R Tramèr; D Carroll; F A Campbell; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

Review 2.  Methodological issues in antiemetic studies.

Authors:  M Aapro
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

3.  Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production.

Authors:  Yelena A Shmist; Igor Goncharov; Maor Eichler; Vladimir Shneyvays; Ahuva Isaac; Zvi Vogel; Asher Shainberg
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

Review 4.  The therapeutic potential of cannabis and cannabinoids.

Authors:  Franjo Grotenhermen; Kirsten Müller-Vahl
Journal:  Dtsch Arztebl Int       Date:  2012-07-23       Impact factor: 5.594

5.  Nausea and vomiting as major complications of cancer chemotherapy.

Authors:  J Laszlo
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

Review 6.  [Review of cannabinoids in the treatment of nausea and vomiting].

Authors:  L Radbruch; F Nauck
Journal:  Schmerz       Date:  2004-08       Impact factor: 1.107

Review 7.  Adverse effects of medical cannabinoids: a systematic review.

Authors:  Tongtong Wang; Jean-Paul Collet; Stan Shapiro; Mark A Ware
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

Review 8.  Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol.

Authors:  Katarina Černe
Journal:  Arh Hig Rada Toksikol       Date:  2020-03-01       Impact factor: 1.948

Review 9.  Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Authors:  Ainhoa Bilbao; Rainer Spanagel
Journal:  BMC Med       Date:  2022-08-19       Impact factor: 11.150

Review 10.  Cannabinoid Regulation of Acute and Anticipatory Nausea.

Authors:  Erin M Rock; Martin A Sticht; Cheryl L Limebeer; Linda A Parker
Journal:  Cannabis Cannabinoid Res       Date:  2016-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.